Pharmanutra H1 net result rises 8.1% to €9.9 million; sales revenues increase 17.9% to €73 million
Reuters2026/09/11 15:42Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Pharmanutra net sales climbed 17.9% to EUR 73 million in the first half, lifted by international markets and flagship products.
- EBITDA rose 6.2% to EUR 17.5 million, while net profit attributable to shareholders increased 8.1% to EUR 9.9 million.
- Foreign-market net sales jumped 34.8% to EUR 28.2 million, raising their mix to 38.6% from 33.8% a year earlier.
- Net financial position swung to EUR -2.9 million from EUR 11.4 million at end-2025, mainly due to an EUR 11.5 million dividend.
- CEO Roberto Lacorte said new business units and Akern integration are starting to deliver, with second-half net sales expected to rise again.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmanutra S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20106-27-2026_TELEBORSA.pdf), on September 11, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Taiwan Dollar: CBC seen on hold before December hike – DBS
FXStreet•2026/09/11 20:57
Annovis Bio announces special shareholder meeting
Reuters•2026/09/11 20:54
Liberty Star net loss widens 32.28% to $289,301 in Q2 FY26
Reuters•2026/09/11 20:53